AfaSci, Inc. is a pre-clinical stage biotech structured around discovery and development of peptide and small molecule therapies for unmet needs in the pain and neurology space. Currently focused on two therapeutic candidates for neuropathic pain and neuroinflammatory pain - debilitating conditions affecting millions in the United States and an estimated 7-8% of adults worldwide. The firm's two therapeutic candidates are competitively differentiated as novel non-opioid and non-steroidal analgesics. AfaSci also has a drug discovery pipeline focused on Alzheimerâs disease, epilepsy, and sleep disorders.The firm currently (a) Two therapeutic candidates for neuropathic and neuro-inflammatory pain ready for IND-enabling studies. With all the firm's pre-clinical research reviewed/supported by NIH grants, the work has also been validated across multiple peer-reviewed publications. The firm's active collaborations with academic institutions include Stanford, Harvard, UCLA, UC Davis, and Kansas State University. The company leverages a proprietary drug discovery platform for more effective target identification and efficient animal testing, in vivo pharmacology, and electrophysiology studies
